Effect of Immunomodulating Adjuvant Dzherelo (Immunoxel) in HIV Infected Patients Receiving Standard Antiretroviral Therapy
Lyudmila G Nikolaeva1, Tatiana V Maystat1, Yuri L Volyanskii2, Volodymyr S Pylypchuk3, Valery M Frolov4, Galyna A Kutsyna*, 4
Identifiers and Pagination:Year: 2009
First Page: 31
Last Page: 36
Publisher Id: TOVJ-3-31
Article History:Received Date: 19/2/2009
Revision Received Date: 19/3/2009
Acceptance Date: 26/3/2009
Electronic publication date: 5/5/2009
Collection year: 2009
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Open-label, matched-case, comparative trial was conducted in 40 HIV-infected patients to evaluate the adjunct effect of Dzherelo (Immunoxel) on immune and viral parameters. Arm A (n=20) received anti-retroviral therapy (ART) consisting of zidovudine, lamivudine, and efavirenz and arm B (n=20) received ART with Dzherelo. After 2 months total T-lymphocytes increased in ART recipients from 664 to 819 cells/μl (P=0.06), whereas in Dzherelo recipients they rose from 595 to 785(P=0.03). The CD4 T-cells expanded by 57.3% (218 to 343; P=0.002) in the ART arm and by 93.5% (184 to 356; P=0.004) in the Dzherelo arm. The accrual in absolute and relative number of CD8+ lymphocytes in ART and in the Dzherelo recipients was 43.2% (2.7%) and 50.4% (-0.5%) respectively. The CD4/CD8 ratio in Dzherelo recipients increased from 1.495 to 1.940 (P=0.03) but insignificant in the control: 1.418 to 1.613 (P=0.14). Activated CD3+ HLADR+ T-cells increased from 209 to 264 (P=0.02) and from 161 to 348 (P=0.0007) in ART and Dzherelo recipients respectively. No changes in CD20+ B-lymphocytes were seen in the control, but in Dzherelo patients they declined from 509 to 333 (P=0.00008). The proportion of CD3- CD16+CD56+ NK cells was not affected by ART but addition of Dzherelo raised NK cells from 11.2% to 17.1% (P=0.0001). About three-quarters (14/19) of patients on ART displayed decrease in viral load (1718 to 1419 copies/ml; P=0.008), while 95% of patients on Dzherelo had a decrease (1793 to 1368; P=0.001). Dzherelo has a favorable effect on the immune status and viral burden when given as an immunomodulating adjunct to ART.
Antiretroviral drug resistance, drug toxicity and adherence are major concerns in clinical management of HIV infection . The combination of antiviral drugs, such as highly active antiretroviral therapy (HAART), may prevent HIV from mutating and spreading, allowing patients to rebuild their immune system to the same levels as in normal individuals . On the other hand, the immune activation caused by enhanced immune reaction to HIV is now recognized as a cause of depletion of CD4 T-cells and resulting immunodeficiency . These problems are a driving force for research on new therapies that can provide suitable solutions. The most optimal therapeutic solution is an effective and safe immunotherapy that could regulate the immune response in a manner favorable to the host. There are many types of immune modulators that have been used clinically for viral infections, but for HIV the choice of immune interventions is limited .
Ukraine has the highest prevalence of HIV infection in Eastern Europe [5, 6]. Oral immunomodulator Dzherelo is used in Ukraine for the management of HIV infections, including patients co-infected with TB [7-12]. Clinical studies have indicated that Dzherelo can significantly increase CD3 and CD4 T-lymphocyte populations and helps to achieve better clinical response when combined with standard anti-retroviral therapy (ART) consisting of zidovudine (AZT); lamivudine (3TC), and efavirenz (EFV) [7-9]. Dzherelo has been found to decrease the incidence of opportunistic infections and reverse AIDS-associated wasting [7-9]. Dzherelo has also been found to decrease the hepatotoxicity associated with ART [7-9, 12].
Dzherelo was approved in 1997 by the Ministry of Health of Ukraine as an immunomodulating supplement, which so far has been used by over 500,000 individuals for various indications including chronic bacterial and viral infections such as TB and HIV, autoimmune diseases, and malignancy . Dzherelo contains concentrated aqueous-alcohol extract from medicinal plants such as Aloe, Common knotgrass, Yarrow, Purple coneflower, Tutsan, Centaury, Snowball tree berries, Nettle, Dandelion, Sweet-sedge, Oregano, Marigold, Seabuckthorn fruit, Elecampane, Tormentil, Greater plantain, Wormwood, Siberian golden root, Cottonweed, Licorice, Fennel, Birch tree fungus, Thyme, Three-lobe Beggarticks, Sage, Dog rose fruit, and Juniper fruit. Our study was aimed at evaluating the effect of Dzherelo on immune cell subsets and viral load among HIV patients treated with standard ART in comparison to a control population which received ART alone.
MATERIALS AND METHODS
The design of this study is matched case comparative study. The patients, aged 20-59 years, have been selected and divided into arms A (ART alone) and B (Dzherelo added), each consisting of 20 patients matched by their average initial CD4 counts, gender ratio and age. The average (median) age in arms A and B was 33.9 (31.5) and 32.8 (31) years. The proportion of males and females was 15/5 and 17/3 in arms A and B respectively. Patients were in advanced clinical stage of HIV infection with average baseline CD4+ T-cell count being below 200 cells/microliter. Another inclusion criterion was the lack of any form of anti-retroviral therapy prior to the trial. The diagnosis of HIV infection was established by standard ELISA test further confirmed by Western blot analysis. The participation in this trial was voluntary and patients were enrolled only after signing the written consent indicating that they were free to withdraw from the study at any time. The conduct of the trial was approved by the Ethics board of the AIDS center in compliance with the Helsinki declaration.
None of the patients received anti-retroviral therapy prior to the trial. After initial screening, qualifying patients were randomly divided in two arms: arm A was prescribed: zidovudine (AZT) at 300 mg doses twice-daily; lamivudine (3TC) 150 mg tablets twice-daily, and efavirenz (EFV) 600 mg dose once-daily. The arm B received, in addition to the same three-drug ART, twice per day dose of Dzherelo which was given as 50 drops diluted in 100 ml of water.
Immunophenotyping of Lymphocyte Subpopulations
The samples of peripheral blood of patients with HIV were analyzed using commercially available Clonospectr panel of monoclonal antibodies against surface antigens of lymphocytes (MedBioSpectr, Moscow, Russia). Assays were carried out at study entry and after 1 and 2 months on the therapy. The absolute and percent values of the following subpopulations were assessed in a blinded fashion by fluorescent microscopy: total T lymphocytes (CD3+); helper T lymphocytes (CD3+CD4+); cytotoxic T lymphocytes (CD3+CD8+); B lymphocytes (CD20+); natural killer or NK cells (CD3-CD16+CD56+); and activated T lymphocytes (CD3+HLA-DR+). In addition the changes in the ratio between CD4 and CD8 cells were evaluated as a part of assessment of the immune status of patients. The samples of the blood from 19 healthy blood donors were analyzed as a reference for normal values.
Stored frozen samples of plasma were processed in bulk by using commercially available PCR kit (AmpliSense HIV-1, Central Research Institute of Epidemiology, Moscow, Russia) designed for quantitative analysis of HIV-RNA copies. Tests were carried out at baseline and after two months of the therapy.
The obtained results were analyzed with the aid of statistical software STATMOST (Datamost, South Sandy, UT). The baseline cell numbers relative to 1st and 2nd months of follow-up were evaluated by paired Student t-test. The non-parametric values such as viral load were analyzed by Wilcoxon signed-rank test. All statistical calculations were per intent-to-treat basis or the total number of available patients without subgrouping them into responders and non-responders. The resulting probability values were considered as significant at the cut-off levels of P≤0.05.
After one month on the therapy there was a clear distinction between recipients of ART alone and those who received ART along with the daily dose of Dzherelo. This disparity became even more evident at the end of 2nd month of therapy. Some but not all immune markers of lymphocyte subsets were impacted in a statistically significant manner. The changes in viral load among HIV patients of both groups also reached statistical significance. These findings are described in detail below.
CD3+ Total T Lymphocytes
After one month on ART alone the absolute and percent (%) values of total CD3+ lymphocytes per microliter of blood changed in a statistically discordant manner i.e. from a baseline 664(36.5%) to 743(38.4%) with P=0.13(P=0.03), as analyzed by paired Student t-test. Similarly, after one month in the group receiving Dzherelo there was a statistical discordance between absolute and percent CD3+ values: from 595(34.2%) to 664(40.5%); P=0.14(P=0.0003). After 2 months the number of total CD3+ lymphocytes increased further to 785 (43.9%) in arm B (Dzherelo) i.e. P=0.034 (P=0.0002), whereas in the control it increased to 819 (39.8%) cells, with probability values P=0.06 (P=0.03) respectively. The accrual in total lymphocytes from baseline to the end of follow-up, was 23.3% and 31.9% for absolute and 9% and 28.4% for relative numbers in control and Dzherelo arms respectively (Fig. 1).
Changes in absolute and relative numbers of peripheral blood cell subpopulations at 2 months post-therapy as expressed in percentage values (Y-axis) relative to their respective baseline levels.
CD4+ T Lymphocytes
The trends similar to those of total CD3+ lymphocytes were observed when CD3+CD4+ lymphocyte subsets were analyzed. Significant changes were seen in the ART alone arm after one month i.e. 218(30.3%) to 295(35.2%); P=0.007(P=0.02). Similarly in the Dzherelo arm the helper T-cell counts rose in a significant manner from 184(28.4%) to 254(34.8%) cells; P=0.03(P=0.0002). At the end of 2nd month lymphocyte subsets rose to 343(35.7%) and 356(38%) with probability values P=0.002(P=0.01) and P=0.004 (P=0.0005) for arms A and B respectively. When study completion results of ART and Dzherelo recipients were calculated in terms of accrual in CD4+ lymphocytes relative to entry levels there was an increase of 57.3%(17.8%) and 93.5%(33.8%) in absolute and relative values.
CD8+ T Lymphocytes
The changes observed in CD3+CD8+ cytotoxic T-cell population are different from those seen with helper cells. In the ART alone group, absolute but not relative numbers of CD8+ cells increased in a significant manner from 155(22.6%) to 203(24%); P=0.014 (P=0.21), while in the Dzherelo group the changes were insignificant in both categories i.e. from 123(19.8%) to 152(20.3%); P=0.08(P=0.28). At the end of the 2nd month the CTL population in the ART group was still above baseline i.e. 222 cells (23.2%), an accrual that was statistically significant for absolute numbers P=0.009 but not significant when relative numbers were evaluated (P=0.39). Similarly, among Dzherelo recipients the 2nd month absolute but not relative numbers of CD8 cells also increased in a significant manner, from baseline levels 123(19.8%) to 185(19.7%), with P values being 0.013 and 0.39 respectively. When study completion results of ART and Dzherelo recipients were calculated in terms of accrual in CD8+ lymphocytes as compared to baseline levels there was an accrual corresponding to 43.2%(2.7%) and 50.4%(-0.5%) of absolute and relative values respectively.
The differential changes in CD4 and CD8 lymphocyte numbers affected the CD4/CD8 ratio in patients on ART alone regimen as early as one month after treatment initiation. The ratio increased from baseline value 1.418 to 1.532 but without reaching significance (P=0.23). The CD4/CD8 ratio among Dzherelo recipients increased from 1.495 to 1.671, which was also above the cut-off value (P=0.09). The disparity between CD4 and CD8 lymphocytes had progressed further by the end of 2nd month. Among the ART alone patients the ratio increased to 1.613(P=0.14), while in Dzherelo group the ratio rose to 1.940 (P=0.03). When study end results of ART and Dzherelo recipients were calculated in terms of relative accrual from baseline levels there was a gain of 13.8% and 29.3% respectively.
CD3+HLA-DR+ Activated Lymphocytes
The absolute and percent numbers of activated CD3+HLA-DR+ T cells increased steadily in ART group from 209 (24.7%) to 231 (26.6%), and then to 264 (27.8%) with P=0.13(P=0.04) and P=0.02(P=0.02) at the end of first and second months respectively. In Dzherelo recipients this subpopulation increased at higher incremental rate from 161(25.9%) to 247(35.1%) and then to 348(36.5%) with P=0.01(P=0.0004) and P=0.0007(P=0.0003) respectively. The relative accrual in absolute and relative numbers in ART group was 26.3%(12.6%) at the end of the 2nd month. During the same time period the patients who received Dzherelo experienced 216%(40.9%) increase over baseline in absolute and relative numbers respectively.
CD20+ B Lymphocytes
In patients who received ART alone B-cell counts moved up slightly but differences were not statistically significant at either time point. At the end of the 1st month they rose from 522 (28.3%) to 526 (28.2%) cells P=0.43 (P=0.37) and at study conclusion they reached 542 (27.3%); P=0.47 (P=0.22). However, patients who received Dzherelo displayed a significant decrease in CD20+ lymphocyte numbers. The entry value of 509 (31%) cells went down to 367 (24.9%) at the 1st month and then to 333 (23.3%) toward end of the study with probability values P=0.003 (P=0.0002) and P=0.00008 (P=0.00002) respectively. At this time point the number of CD20-expressing cells became indistinguishable from the value of normal donors i.e. 337 cells (22.2%).
CD3-CD16+CD56+ NK Cells
The relative numbers of NK cells identified as CD3-negative but CD16+CD56+ population were not significantly affected by ART alone therapy: from baseline level of 19.3% they rose to 21.2% (P=0.17), and then to 22.3% at study conclusion (P=0.12). The addition of daily dose of Dzherelo, however, had a strong effect on gain of NK cells. The patients who started with an average 11.2% NK cells had their numbers increased to 13.7% (P=0.004), which further increased to 17.1% (P=0.0001). Thus, at the end of 2-month of therapy, the patients on Dzherelo had experienced 52.7% increase in NK cells as compared to baseline levels.
Lymphocyte Subsets in Normal Blood Donors
Samples of the peripheral blood of 19 healthy individuals were analyzed to obtain the normal distribution values of peripheral blood subsets. The average number of absolute and relative (%) CD3 lymphocytes were 1,370±169 cells/μl (52.9±6.8). The values of CD4 and CD8 lymphocytes were 622±89 (35.9±4.3) and 349±42 (19.9±2.1) respectively, with the ratio being 1.76±0.19. The HLA-DR+ expressing activated T-cells represented 585±131 cells (35.2±3.5). The absolute and percent figures of CD20+ B-lymphocytes per μl of blood were 337±52 (22.2±4.3). The percentage of NK cells was 12.2±2.9%.
The viral load, as measured by plasma RNA-PCR at baseline and at the end of 2nd month, decreased in the ART group (1718 to 1419 copies/ml; P=0.008), as analyzed by Wilcoxon signed rank test. In the Dzherelo arm the viral load decreased from 1793 to 1368 copies; P=0.001). About three-quarters (14/19) of patients on ART alone displayed the decrease in viral load, while 18 out of 19 of patients on Dzherelo (95%) had a reduction in their number of viral copies (Table 1).
Effect of 2-Month ART without or with Dzherelo on HIV-RNA Plasma Levels
|Patient No.||Arm A
HIV Patients on ART Alone (N=20)
HIV Patients on ART + Dzherelo (N=20)
|HIV-RNA Copies/ml at Baseline||HIV-RNA Copies/ml at 2nd Month||Difference Compared to Baseline||HIV-RNA Copies/ml at Baseline||HIV-RNA Copies/ml at 2nd Month||Difference Compared to Baseline|
Wilcoxon signed rank test; P=0.008
Wilcoxon signed rank test; P=0.001
ND: not done.
In prior studies Dzherelo has been shown to influence positively CD3 and CD4 lymphocyte numbers [7-9]. Dzherelo reduced the incidence of opportunistic infections and reversed body weight loss associated with HIV [7, 10]. It has also been shown to reduce the toxic side effects of ART, hepatotoxicity in particular [7, 9, 12]. For example, elevated liver aminopeptidase ALT and AST levels caused by ART have been shown to return back to normal levels when Dzherelo is used. However, these studies have not dealt with the effect of Dzherelo on other immune markers and viral load.
Our 2-month study conducted in prior anti-retroviral drug-naïve population reveals that when Dzherelo is added to ART there are significant benefits associated with this intervention. In our hands Dzherelo appears to display the same effect as reported by independent investigators. Our results indicate that administration of Dzherelo along with ART can produce significant increase in total CD3+ lymphocytes, CD4+ helper cells, better CD4/CD8 ratio, higher number of CD3+HLA-DR+ activated lymphocytes, and NK cells. Dzherelo appears to increase absolute but not relative numbers of CD8+ T lymphocytes and reduce significantly CD20+ B lymphocyte subpopulation. Furthermore, Dzherelo appears to contribute to the inhibitory effect of ART on viral replication resulting in statistically significant lower viral load in a higher proportion of patients (Table 1). These effects could not be attributed to heterogeneity of patient populations in two tightly matched treatment groups in which none of the initial characteristics in terms of age, gender, disease stage and cell counts were statistically different at baseline.
It is well established that elevated CD3 and CD4 counts and higher CD4/CD8 ratio are associated with better prognosis in patients with HIV . For this reason Dzherelo is likely to influence positively the outcome of treatment and disease progression in our study population. Similarly, viral load is a predictor of HIV disease progression, its persistent elevation in HIV infected patients being indicative of poor prognosis [14, 15]. While there were earlier indications that Dzherelo may reduce the viral burden, our study is the first to report this phenomenon in a systematic fashion. Despite the fact that the HIV RNA levels had decreased by less than a log the difference between baseline and outcome levels was highly significant (Table 1). While baseline and outcome viral burden appeared unusually low, this may have been due to the PCR kit we have used in this study; since we have seen similar low numbers in our study dealing with TB/HIV dually infected patients . Nevertheless, it is likely that the observed effect on viral load is mediated by immune cells since Dzherelo does not have a direct effect on HIV replication .
Our study reveals that at the end of study the patients on Dzherelo had absolute and relative numbers of CD3+HLA-DR+ cells equal to 348 (36.5%) or 216% and 40.9% more compared to baseline, whereas patients on ART had their numbers increased to a maximum 26.3%. Compared to normal blood donors the relative numbers in Dzherelo group were comparable but absolute values were lower i.e. 35.2% and 585 respectively. It has been shown that HIV+ patients usually have significantly higher HLA-DR expressing cells, which may negatively affect T cell immune responses and facilitate the disease progression . Others suggested that the increase in HLA-DR-reactive T lymphocytes was not predictive of clinical outcome . We do not know to which subpopulation of T lymphocytes the CD3+HLA-DR+ activated cells belong. Judging from relative changes in CD4 and CD8 subsets it is possible that the activation marker is expressed on CD4 cells. However, due to limitations of the commercially available panel of antibodies preventing simultaneous staining with multiple fluorescent markers, we have not been able to verify this possibility. This needs to be ascertained in future studies.
Although a great deal of information is available about the role of T lymphocytes in the immune response against HIV comparatively little is understood regarding the involvement of B lymphocytes. Our results show very little variation in CD20+ B-cell numbers in the ART-treated arm but a highly significant decrease in Dzherelo recipients to levels that were identical to those seen in normal individuals i.e. 333 (23.3%) vs 337 (22.2%). Contrarily, the absolute and relative numbers of B-cells were more than double in ART recipients. We do not know what the significance of this observation is. It has been reported that the expression of CD20 is consistently higher when B cells from HIV-infected individuals are compared with those from uninfected subjects . Thus, we can only assert that Dzherelo is highly effective in restoring the normal balance of CD20 expressing B-cells.
We have observed the drastic difference between two arms in relative number of NK cells after 2 months of therapy. When compared to the entry levels the patients on Dzherelo had 52.7% more of NK cells whereas the population of these cells had increased by only 15.5% in ART alone group. The role of NK cells in HIV remains unclear. While some indicated that higher number of NK cells is critical for controlling HIV, others indicated that the quality but not the number of cells is critical in defending the host against HIV infection [19, 20]. This discrepancy probably stems from differences in the design of studies some of which were based on measurement of functional activity but others were based on the enumeration of cells at various stages of the disease. Since we have not measured the functional activity of NK cells we do not know what is the significance of this phenomenon in regard to the immunopathogenesis of HIV. Based on the evidence that Dzherelo is highly effective as an immune adjuvant to ART we can only speculate that in our case the increase in NK numbers might be beneficial to the host.
Many studies have been conducted aimed at determining the phenotype of immune cells in HIV infection. While there is a consensus that the immune response plays a critical role in determining the clinical outcome much more has to be learned in order to have a clear picture of cellular events during the course of disease. The understanding of the immune mechanism controlling HIV may result in design of better vaccines and immunotherapies. Therefore, high priority should be given to efforts of prevention and treatment of infectious complications in these patients.
Currently available chemotherapy for the treatment of HIV is not ideal, requiring multiple drugs to be taken in combination for the rest of life of a patient . The extended duration of therapy, coupled with the side effects, often results in poor patient adherence, treatment failure, and the emergence of drug resistance with major social and economic implications. We believe that immunotherapy is an indispensable part of therapeutic strategies against HIV. The development of novel immune-based therapies is an urgent objective for anti-HIV drug discovery. Many immune interventions are available against bacteria, protozoa, fungi and viruses. While often effective the mechanism of many immunomodulators is poorly understood. This downside should be balanced against clinically confirmed benefits. Our study provides an early glimpse into the putative immune mechanism of Dzherelo, which has been successfully used as an immune adjunct to HIV therapy in Ukraine during last ten years [7-12]. Additional studies are needed to develop better understanding of Dzherelo’s properties and to supplement the current arsenal of HIV therapies.
We thank all participants who volunteered in this study. The generosity of Ekomed in supplying Dzherelo is appreciated very much. The tireless support of clinical staff and technicians who contributed to this study has been of tremendous help to bring this study to fruition. The discussion with other investigators of Dzherelo who shared their insight and provided helpful suggestions has guided our study and we are thankful to them all. This work was presented in part at the Keystone Symposia on HIV Pathogenesis and HIV Vaccines, March 27 - Apr 1, 2008, Banff, Alberta, Canada, through a grant from Bill and Melinda Gates Foundation’s Global Health Travel Award, which is gratefully acknowledged.
CONFLICT OF INTEREST
All authors, except Volodymyr Pylypchuk, declare no conflict of interest. Pylypchuk is the inventor of Dzherelo (Immunoxel) and Director of Ekomed company.